Cash and cash equivalents, as of March 31, 2025, were $92.2 million, as compared to $102.7 million as of December 31, 2024. Based on current plans and assumptions, the Company expects that its existing cash and cash equivalents will be sufficient to fund its current operating plan into the first quarter of 2027.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CADL:
- Candel Therapeutics’ CAN-2409 Trial Results Accepted at ASCO
- Promising Clinical Outcomes and Strategic Advances Boost Candel Therapeutics’ CAN-2409 Potential in Oncology
- Candel Therapeutics announces publication of Phase 1b trial data on CAN-2409
- Promising Survival Data and Strategic Partnerships Drive Buy Rating for Candel Therapeutics
- Promising CAN-2409 Trial Results Drive Buy Rating for Candel Therapeutics